Imara (IMRA) Stock Highlights

45.38 | +0.38%

2025-04-05 07:42:46

Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small-molecule inhibitor of phosphodiesterase-9, or PDE9.

Statistics

Range Today

44.89 45.39

Volume Today 1.28K

Range 1 Year

null null

Volume 1 Year 0

Range 3 Year

null 6.32

Volume 3 Year 251.45M

Range 10 Year

null 62.71

Volume 10 Year 321.36M

Highlights

Current Price 45.38

Performance

Latest +0.38%

1 Month -1.73%

3 Months -1.73%

6 Months -1.73%

1 Year -1.73%

3 Years +2421.11%

5 Years +183.09%

10 Years +224.14%

Benchmarks

Market Capitalization

236 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

151 / 368

Free Cashflow

144 / 352

Performance 5 years

47 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.